References
- Aymard G, Warot D, Démolis P, Giudicelli JF, Lechat P, Le Guern ME, et al. Comparative pharmacokinetics and pharmacodynamics of intravenous and oral nefopam in healthy volunteers. Pharmacol Toxicol 2003;92:279–86
- Kakkar M, Derry S, Moore RA, McQuay HJ. Single dose oral nefopam for acute postoperative pain in adults. Cochrane Database Syst Rev 2009;3:CD007442
- Klohs MW, Draper MD, Petracek FJ, Ginzel KH, Re ON. Benzoxazocines: A new chemical class of centrally acting skeletal muscle relaxants. Arzneimittelforschung 1972;22:132–133
- Marazziti D, Rotondo A, Ambrogi F, Cassano GB. Analgesia by nefopam: Does it act through serotonin? Drugs Exp Clin Res 1991;17:259–61
- Song CW. Effect of local hyperthermia on blood-flow and microenvironment: A review. Cancer Res 1984;44(Suppl10):S4721–30
- Wismeth C, Dudel C, Pascher C, Ramm P, Pietsch T, Hirschmann B, et al. Transcranial electro-hyperthermia combined with alkylating chemotherapy in patients with relapsed high-grade gliomas – phase I clinical results. J Neurooncol 2010;98:395–405
- Szasz A, Iluri N, Szasz O. Local hyperthermia in oncology. To choose or not to choose? In: Huilgol N, editor. Hyperthermia. Rijeka, Croatia: In Tech; 2013. pp 1–82. doi: 10.5772/52208
- Fiorentini G, Giovanis P, Rossi S, Dentico P, Paola R, Turrisi G, et al. A phase II clinical study on relapsed malignant gliomas treated with electro-hyperthermia. In Vivo 2006;20:721–4
- Andocs G, Szasz O, Szasz A. Oncothermia treatment of cancer: From the laboratory to clinic. Electromagn Biol Med 2009;28:148–65
- Szasz A. Challenges and solutions in oncological hyperthermia. Thermal Med 2013;29:1–23
- Ahmad M, Yaqoob M, Murtaza G. Study of pharmacokinetics and comparative bioavailability of nefopam 30 mg tablets in twelve fasting healthy Pakistani male young subjects: Single-dose, randomized, two-period, two-treatment, and two-way cross-over design. Med Princ Pract 2012;21:271–6
- Song CW, Park HJ, Lee CK, Griffin R. Implication of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment. Int J Hyperthermia 2005;21:761–7
- Ausmus PL, Wilke AV, Frazier DL. Effects of hyperthermia on blood flow and cis-diamminedichloroplatinum(II) pharmacokinetics in murine mammary adenocarcinomas. Cancer Res 1992;52:4965–8
- Michel T. The use of heat and cold in pain modulation. Massachusetts General Hospital and MGH Institute for Health Professions. Available at http://www2.massgeneral.org/painrelief/pain%20topics/heat_cold.pdf (accessed October 2012)
- Seegenschmiedt MH, Vernon CC. A Historical perspective on hyperthermia in oncology. In: Seegenschmiedt MH, Fessenden P, Vernon CC, editors. Thermoradiotherapy and Thermochemiotherapy: Biology, Physiology, Physics. Volume 1. Berlin: Springer Verlag; 1996. pp 3–46
- Kim YP, Choi Y, Kim S, Park YS, Oh IJ, Kim KS, et al. Conventional cancer treatment alone or with regional hyperthermia for pain relief in lung cancer: A case-control study. Complement Ther Med 2015;23:381–7
- Issels RD, Lindner LH, Verweij J, Wust P, Reichardt P, Schem BC, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft tissue sarcoma: A randomised phase 3 multicentre study. Lancet Oncol 2010;11:561–70
- Mohamed F, Marchettini P, Stuart OA, Urano M, Suqarbaker PH. Thermal enhancement of new chemotherpeutic agents at moderate hyperthermia. Ann Surg Oncol 2003;10:463–8
- Fotopoulou C, Cho CH, Kraetschell R, Gellermann J, Wust P, Lichtenegger W, et al. Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse: Results of a pilot study. Int J Hyperthermia 2010;26:118–26
- Inman BA, Stauffer PR, Craciunescu OA, Maccarini PF, Dewhirst MW, Vujaskovic Z. A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer. Int J Hyperthermia 2014;30:171–5
- Angele MK, Albertsmeier M, Prix NJ, Hohenberger P, Abdel-Rahman S, Dieterle N, et al. Effectiveness of regional hyperthermia with chemotherapy for high-risk retroperitoneal and abdominal soft-tissue sarcoma after complete surgical resection: A subgroup analysis of a randomized phase-III multicenter study. Ann Surg 2014;260:749–56
- US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry. Drug Interaction Studies – Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. Silver Spring, MD: Food and Drug Administration, 2012